Mark Carthy, Managing Partner of Orion Equity Partners, invests in early-stage healthcare and biotechnology ventures developing products. See contact routes.
Mark Carthy, Managing Partner of Orion Equity Partners, invests in early-stage healthcare and biotechnology ventures developing products for major medical needs, with typical check sizes ranging from $1–5 million. His notable portfolio includes Solexa (acquired by Illumina for ~$600M), PowderMed (acquired by Pfizer), and AnTolRx, where he serves as CEO and director. Carthy’s distinctive thesis emphasizes capital-efficient value creation for science-driven health technologies that achieve strategic exits.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Boston when building a target list.
Investors like Mark Carthy · Full investor directory · Investor access · Company funding database